Targeted Peptide Selection and Validation

靶向肽选择和验证

• 批准号: 8555331
• 负责人: Thomas D Wang
• 金额: $ 21.31万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8555331
• 关键词: Adenocarcinoma; Barrett Esophagus; Binding; Biopsy; Cell surface; Cells; Clinical; Clinical Research; Cultured Cells; Detection; Dysplasia; Endoscopes; Endoscopy; Epidermal Growth Factor Receptor; Esophageal mucous membrane; Excision; Extracellular Domain; Fiber; Fluorescence; Future; Gene Amplification; Gene Targeting; Human Subject Research; Image; Individual; Investigation; Label; Microscope; Multi-Institutional Clinical Trial; Peptides; Performance; Pharmaceutical Preparations; Pharmacology and Toxicology; Phase; Proteins; Protocols documentation; Safety; Scanning; Screening for cancer; Specimen; Tissues; Validation; base; fluorophore; instrument; milligram; overexpression; phase 1 study; prototype; validation studies

A panel of 5 peptides will be developed that have specific binding activity to amplified and/or over expressed gene targets identified in Project 1. Validation of preferential binding will be performed to purified proteins and to cells in culture transfected with gene targets. Validation of selective binding will then be performed to high grade dysplasia and early adenocarcinoma in Barrett's esophagus on fresh endoscopic mucosal resection specimens and tissue biopsies in Core C using the multi-spectral scanning fiber endoscope (SFE) developed in Project 3. Rigorous statistical analysis will be performed by Core B. Phase 1 clinical studies of the individual peptides assigned to three fluorescent-labels will be performed to establish safety of this integrated imaging strategy for a future multi-center clinical validation study.

将开发一个由5个肽组成的小组，这些肽具有特定的结合活性，可以扩增